macroenviron reit buy rais pt
trikafta sustain launch success met rais revenu
guidanc continu trikafta launch treatment
cystic fibrosi cf patient age older least one
mutat note compani estim major
approxim current elig patient initi
therapi manag point includ new initi
well patient transit vertex therapi
believ transit detriment platform overal
commerci momentum importantli point traction
occur despit larger context global pandem
manag emphas absenc impact suppli chain
continu discuss pipelin impact includ
paus screen enrol note key expans opportun
cf continu forward specif includ on-going review
tripl combin approv eu patient age older
least one mutat plan tripl combin snda
submiss fda children age year old
least one mutat pend readout fulli enrol
phase trial note could potenti address earlier stage
diseas develop recent kalydeco submiss
approv infant age less month old
europ note would build upon current approv infant
age month account adjust model incorpor
provid revenu guidanc discuss maintain
buy rate rais price target
pipelin impact temporari focu shift safeti amid continu
develop compani note temporari paus patient
screen enrol phase studi
defici aatd exampl manag quick mention
studi remain activ initi new clinic trial site
futur enrol oral small molecul corrector util
correct approach prevent protein misfold aatd
highlight although enrol paus compani
process re-initi trial site site select region
abl continu likewis note compani
second small molecul corrector aatd complet phase
readi plan phase proof-of-concept dose-rang trial
anticip overal note chronic weekli augment
therapi alon replac consid cure
address progress liver manifest aatd believ
target prevent z-protein misfold liver
otherwis aggreg ultim pro-inflammatori lung
could conceiv serv possibl aatd cure continu
believ one promis prospect affect patient
drug affect lung liver diseas note vertex
assert small molecul corrector protein misfold could
inde address liver lung diseas aatd manifest
definit distribut analyst rate analyst certif disclosur pleas refer page report
number vertex report total revenu compar consensu first quarter research
develop cost sell gener administr expens
compani report net incom quarter march compani report
cash equival vertex guid total revenu view conserv current
project total revenu high end provid guidanc estim continu trikafta
traction earlier launch stage
valuat risk account adjust model incorpor provid revenu guidanc
rais price target new price target base equal weight composit
multipl tax dilut ep discount back
 npv discount rate termin growth rate risk invest thesi target price
includ failur kalydeco orkambi tezacaftor combin clinic studi
failur kalydeco orkambi symdeko trikafta achiev peak sale revenu product competit
mm except per share valu
total orkambi revenu
incivo royalti janssen
hiv proteas inhibitor royalti gsk
revenu
revenu
revenu
revenu
revenu
chang fair valu deriv instrument
provis incom tax
loss attribut non-controlling interest
discount
sensit ep estim
dcf analysi flow valu ms
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc vrtx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl april
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein matthew caufield alicia yin ph certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur vertex
pharmaceut inc includ without limit option right warrant futur long short posit
march neither firm affili benefici class common equiti secur
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
